オプションチェーンは、Cigna Groupの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Cigna Groupの市場センチメントを評価します。.

Cigna Group (NYSE:CI) 株価情報, オプションチェーン

THE CIGNA GROUP

Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.

Cigna

The Cigna Group

Citizens, Inc. Class A Common Stock ($1.00 Par)

Citizens Inc

CHINA MENGNIU DAIRY CO by China Mengniu Dairy Co., Ltd.

China Mengniu Dairy Co Ltd

CHINA MENGNIU DARY UN/ADR by China Mengniu Dairy Co., Ltd.

CHAMPION IRON LTD by Champion Iron Limited

Champion Iron Ltd

CHINA SCORE INC by China Score, Inc.

Grupo Cibest S.A. American Depositary Shares each representing four Preferred Shares

BanColombia SA

COMML INTL BK S/ADR by Commercial International Bank Ltd.

Commercial International Bank (Egypt) CIB

CIB MARINE BANCSHARES by CIB Marine Bancshares, Inc.

CIB Marine Bancshares Inc

COMMUTY INV BANCORP INC by Community Investors Bancorp, Inc.

Community Investors Bancorp Inc

First Trust NASDAQ Cybersecurity ETF

CIBL Inc

CION Investment Corporation 7.50% Notes due 2029

CHINA CONSTR BANK H by China Construction Bank Corp.

China Construction Bank Corp

CHINA CONSTR BK UNSP/ADR by China Construction Bank Corp.

SMS ALTERNATIVES INC by SMS Alternatives Inc.

SMS Alternatives Inc

COSCO SHIPPING HLDGS CO by COSCO SHIPPING Holdings Co Ltd.

COSCO SHIPPING Holdings Co Ltd

COSCO SHP HLDG UNSP/ADR by COSCO SHIPPING Holdings Co Ltd.

CONCEPCION INDUSTRIAL CRP by CONCEPCION INDUSTRIAL CORP

Victory Portfolios II VictoryShares International High Div Volatility Wt

CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD.

Ciena Corp

CHIERU CO LTD by CHIERU CO LTD.

CORPORACION INTERAMER B by Corporacion Intramericano Entretenimiento S.A.

Corporacion Interamericana de Entretenimiento SAB de CV

MFS Intermediate High Income Fund Common Stock

Mfs Intermediate High Income Fund

Cipher Mining Inc

Comp En De Mn Cemig ADS American Depositary Shares

Cia Energetica DE Minas Gerais - Cemig

Comp En De Mn Cemig ADS American Depositary Receipts

Colliers International Group Inc. - Subordinate Voting Shares

Colliers International Group Inc

Concorde International Group Ltd - Class A Ordinary Shares

Concorde International Group Ltd

CI Games SE

CHINA MERCHANTS BK CO H by China Merchants Bank Co., Ltd.

China Merchants Bank Co Ltd

CHINA MRCHNTS BK UNSP/ADR by China Merchants Bank Co., Ltd.

CB INDUS PRODUCT HLDG BHD by CB Industrial Product Holding BHD

BlackRock Enhanced Large Cap Core Fund, Inc. Common Stock

Blackrock Enhanced Cap&Inc Fund, Inc

CITIC SECURITIES CO LTD H by Citic Securities Co., Ltd.

CITIC Securities Co Ltd

CITIC SECURITIES UNSP/ADR by Citic Securities Co., Ltd.

Tianci International, Inc. - Common Stock

Tianci International Inc

Credit Suisse Asset Management Income Fund, Inc. Common Stock

Credit Suisse Asset Mgmt Income Fund Inc

VictoryShares International Volatility Wtd ETF

CHINA LIFE INS CO H SHS by China Life Insurance Company Limited

China Life Insurance Co Ltd

CAROLINA MILLS INC by Carolina Mills, Inc.

Chimera Investment Corporation Common Stock

Chimera Investment Corp

CIMB GROUP HLDGS BHD ORD by CIMB Group Holdings BHD

CIMB Group Holdings Bhd

CIMC ENRIC HLDGS LTD ORD by CIMC Enric Holdings Ltd.

CIMC Enric Holdings Ltd

Chimera Investment Corporation 9.000% Senior Notes due 2029

Chimera Investment Corporation 9.250% Senior Notes due 2029

CIMAREX ENERGY 8 1/8 PFD by Cimarex Energy Co.

Chimera Investment Corporation 8.00% Series A Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

CHINA INDUSTRIAL GRP INC by China Industrial Group, Inc.

Cincinnati Financial Corporation - Common Stock

Cincinnati Financial Corp

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

CHINA TAIPING INS HLD ORD by China Taiping Insurance Holdings Co Ltd.

China Taiping Insurance Holdings Co Ltd

CI&T Inc

CRUCIAL INNOVATIONS CORP by CRUCIAL INNOVATIONS CORP.

City Office REIT Inc

CREATE MEDIC CO LTD by Create Medic Company Ltd.

Create Medic Co Ltd

CION Invt Corp

CENTRAL IRON ORE LIMITED by CENTRAL IRON ORE LIMITED

Central Iron Ore Ltd

Cielo SA ADR

City Office REIT, Inc. 6.625% Series A Cumulative Redeemable Preferred Stock

CORRELATE ENERGY CORP by Correlate Energy Corp.

Correlate Energy Corp

JPMorgan Exchange-Traded Fund Trust Sustainable Consumption ETF

Cirus Foundation

CirTran Corp

Ciscom Corp

CHINA STEEL CP S/ADR 144A by China Steel Corp.

China Steel Corp

CISO Global Inc

C3is Inc

CHINA STEEL CORP S/GDR by China Steel Corp.

COSCO SHIPPING DEV CO LTD by Cosco Shipping Development Co Ltd.

Cosco Shipping Development Co Ltd

COSCO SHIP DEV UNSP/ADR by Cosco Shipping Development Co Ltd.

CARTICA ACQUISITION CORP L ASHS

CARTICA ACQUISITION CORP USD 1 CL A SHS & 1/2 RED WT EXP

CARTICA ACQUISITION CORP RED WTS

CRITICAL INFRASTUCTRE TCH by Critical Infrastructure Technologies Ltd.

Critical Infrastructure Technologies Ltd

AVALON CORRECTIONAL INC by Avalon Correctional Services, Inc.

Manchester City Fan Token

CITIZENS BANCSHARES CP SC by Citizens Bancshares Corp South Carolina

Citizens Bancshares Corp

Civilization

Civista Bancshares Inc

Civitas Resources Inc

Civitas Resources Inc Warrants (20/01/2026)

Civitas Resources Inc Warrants (20/01/2025)

CTR INVTS&CNSLTNG INC by CTR Investments & Consulting, Inc.

CTR Investments & Consulting Inc

CHINA INDL WASTE MGMT INC by China Industrial Waste Management, Inc.

China Industrial Waste Management Inc

CITZNS FINCL CORP W VA by Citizens Financial Corp. (WV)

Citizens Financial Corp WV

Compx International Inc

CaixaBank SA

CI Financial Corp

COMPASS EMP FDS TR DEVELOPED 500 ENHANCED VOLATILITY WEIGHTED INDEX ETF

CITZNS HOLDINGS CO MISS by Citizens Holding Co.

Citizens Holding Co

After Donald Trump signed an <a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time">executive order</a> slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies facing the potential of compressed margins amid poor pricing power.
What Happened: According to Thomas Shipp, the head of equity research at LPL Financial, the pressure that the <a href="https://www.benzinga.com/news/25/05/45389750/trump-claims-drug-price-crackdown-could-slash-your-prescription-costs-by-59-but-will-big-pharma-fight-it-again">pharmaceutical manufacturers</a> are facing to lower prices domestically, &#8220;has the potential to compress margins by eroding pricing power and would provide a significant headwind to drug manufacturer share prices.&#8221;
However, he explains that the &#8220;middlemen&#8221; or PBMs that facilitate drug distribution and negotiate with pharmaceutical drug manufacturers to lower prescription costs have come under scrutiny for opaque pricing practices, like retaining rebates from drug manufacturers and "spread pricing."
&#8220;PBMs pay pharmacies less than what they charge health plan participants for drugs,&#8221; he said.
Another April 15 <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">executive order</a> signed by Trump called for increased transparency into PBM fees and requested that the role of these middlemen be reevaluated.
CVS Caremark, owned by CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Express Scripts, owned by Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), and OptumRx, owned by UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), are the biggest PBM companies.
Shipp also underscored that PBM savings are expected, but direct price controls pose a longer-term risk for U.S.-heavy drugmakers. Transparency will reveal if PBM margin erosion can prevent deeper manufacturer cuts, he highlights.
&#8220;While many questions remain about how these executive orders will be implemented, after the initial news flow is digested, the net effect appears less detrimental to pharmaceutical drug manufacturers than to PBMs,&#8221; said Shipp.
&#8220;That said, reworking the way Americans buy their medicine is going to take a long time. Along the way, efforts to support direct-to-consumer sales will support both the manufacturers leading the charge and those they partner with for distribution,&#8221; he added.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45465955/ark-invest-takes-swipe-at-mstr-mara-says-bitcoin-treasury-companies-dont-make-sense-fundin">Ark Invest Expert Takes Swipe At MSTR, MARA, Says &#8216;Bitcoin Treasury Companies Don&#8217;t Make Sense:&#8217; &#8216;Funding Purchases With Debt&#8230;Seems Like A Recipe For Disaster&#8217;</a>
Why It Matters: Meanwhile, the billionaire investor and Shark Tank fame, Mark Cuban, called PBMs a &#8220;racket&#8221; in an X post by explaining that they <a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">negotiate rebates and not prices</a>.
&#8220;They negotiate rebates. Not prices. In fact, the big PBMs control more than 95pct of the rebate negotiations. Big brand Pharma companies can&#8217;t negotiate with anyone else. IMO, it&#8217;s a racket,&#8221; he said.
While the April 15 order calls for transparency in pricing, Cuban highlights that 30% of the $4.9 trillion in healthcare spending is attributed to the overhead insurance companies and pricing distortions big PBMs create.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">One of the great lies the big PBM industry tells us is that they are needed to negotiate lower prices. It&#39;s a lie. They negotiate rebates. Not prices. In fact, the big PBMs control more than 95pct of the rebate negotiations. Big brand Pharma companies can&#39;t negotiate with…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1923880717420986860?ref_src=twsrc%5Etfw">May 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Here are the aforementioned PBMs operating companies that have performed in 2025.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>41.41%</td>
<td>8.94%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>16.92%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-42.14%</td>
<td>-43.56%</td>
</tr>
</tbody>
</table>
</figure>
Here are a few pharma-linked ETFs for investors to consider.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-0.28%</td>
<td>-4.66%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-1.20%</td>
<td>-2.03%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.45%</td>
<td>-0.83%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.83%</td>
<td>-1.70%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>11.10%</td>
<td>1.65%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-6.51%</td>
<td>-6.89%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.63%</td>
<td>-24.07%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended higher on Friday. The SPY was up 0.63% to $594.20, while the QQQ advanced 0.44% to $521.51, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45433051/jim-cramer-says-gulf-countries-will-become-the-largest-hyperscalers-in-the-world-following-ai-deals">Jim Cramer Says Gulf Countries Will Become &#8216;Largest Hyperscalers In The World&#8217; After Nvidia&#8217;s 18,000 Blackwell Chip Deal</a></li>
</ul>
Photo courtesy: Rawpixel.com / Shutterstock.com

News

Health Care

Markets

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion

An official report on May 14, 2025 reveals Representative Julie Johnson's recent sale of Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) stock, valued between $223,139 and $2,295,000. The transaction took place on May 14, 2025, as per the May filing.
At this time, Amazon.com shares are trading down 3.06% at $203.82.
<h3>Representative's Recent Trading Activity</h3>
Over the previous three years, Julie Johnson conducted 119 trades, totaling more than $133 thousand. The largest of these were in Tesla and ALLETE stock. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>): $1,001 - $15,000 Purchase</li>
<li>Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>): $1,001 - $15,000 Sale</li>
<li>Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of Julie Johnson's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital One Finl</td>
<td>COF</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-21</td>
</tr>
<tr>
<td>Accenture</td>
<td>ACN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-03-19</td>
</tr>
<tr>
<td>Cigna Group</td>
<td>CI</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-19</td>
</tr>
<tr>
<td>Accenture</td>
<td>ACN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-03-14</td>
</tr>
<tr>
<td>3M</td>
<td>MMM</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-12</td>
</tr>
</tbody>
</table>
Stay informed on Julie Johnson's trades and other members of Congress with our real-time <a href="https://www.benzinga.com/gov-trades/members/julie-johnson">government trades tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

Trading Ideas

General

AMZN

Texas Rep. Julie Johnson Sold Up to $2.29M Worth of Amazon.com Stock

President Donald Trump on Monday signed a sweeping executive order aimed at drastically reducing prescription <a href="https://www.benzinga.com/topic/drug-prices">drug prices in the U.S. </a>
What Happened: The Trump administration wants to tie drug prices to the lowest amount paid in comparable foreign countries — a policy known as <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45381118/cvs-health-cigna-stocks-dip-tuesday-whats-going-on">&#8220;most-favored-nation&#8221; pricing.</a>
The executive order is <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a response</a> to what Trump described as &#8220;unreasonable or discriminatory&#8221; practices abroad. 
"In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard [abroad] with skyrocketing prices at home," Trump said in <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a statement</a>.&nbsp;
Drug manufacturers have 30 days to voluntarily lower prices for prescription drugs in the U.S. to match those paid in other advanced nations.&nbsp;
If companies do not comply, the Department of Health and Human Services, led by Robert F. Kennedy Jr., is tasked with developing rules to enforce most-favored nation (MFN) pricing or other regulatory measures.&nbsp;
The HHS is also instructed to establish mechanisms for Americans to purchase drugs directly from manufacturers at the MFN price, bypassing pharmacy benefit managers (PBMs) and other intermediaries.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom?utm_source=articleShare">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>&nbsp;
Why It Matters: The executive order is a rare show of common ground between the Trump administration and Democratic leaders like Senator Bernie Sanders, who has long fought for laws aimed at making medicine more affordable.
And Trump has tried this before. During his first term, he signed a similar <a href="https://trumpwhitehouse.archives.gov/presidential-actions/executive-order-lowering-drug-prices-putting-america-first-2/">order</a> that the courts ultimately blocked after the pharmaceutical industry lobbied against it.
Sanders fears the same thing might happen again. In a <a href="https://bsky.app/profile/did:plc:upw5n2uwhzubjajdtqaufsek/post/3loyh44tra225?ref_src=embed&amp;ref_url=https%253A%252F%252Fwww.commondreams.org%252Fnews%252Ftrump-executive-order-drug-prices">post</a> on the Bluesky social network, he agreed that it is &#8220;an outrage that the American people pay, by far, the highest prices in the world for prescription drugs.&#8221;
&#8220;As Trump well knows, his executive order will be thrown out by the courts,&#8221; said Sanders. &#8220;If Trump is serious about making real change rather than just issuing a press release, he will support legislation I will soon be introducing to make sure we pay no more for prescription drugs than people in other major countries. If Republicans and Democrats come together on this legislation, we can get it passed in a few weeks.&#8221;
Pharmaceutical stocks dropped in Monday's premarket trading, but recovered into positive territory by the market close.
Analysts and investors decided the order was less-specific than feared and likely to be challenged in court.&nbsp;
"A drug pricing announcement had been expected for a while now and had weighed on stocks in this sector, so the official executive order doesn&#8217;t seem to be impacting sentiment too much,&#8221; said James Harlow, senior vice president at Novare Capital Management, per Reuters.&nbsp;
In contrast, Trump&#8217;s comments of &#8220;cutting out the middlemen&#8221; weighed on shares of companies that own pharmacy benefit managers like The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and UnitedHeath Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).&nbsp;
"I would cut out the middlemen," Trump said. "Everybody should equalize. Everybody should pay the same price."
Shares of UnitedHealth plunged Tuesday after<a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance"> the company</a> pulled its 2025 outlook, citing that care activity continued to accelerate and CEO Andrew Witty unexpectedly resigned.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says?utm_source=articleShare">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black&nbsp;</a>
What To Watch: The executive order threatens the PBM business model by enabling direct-to-consumer drug purchases, which could significantly reduce the need for PBMs&#8217; negotiating and administrative services. However, legal experts have raised concerns about the legality of direct-to-consumer sales.&nbsp;
"This order's suggestion of broader or direct-to-consumer importation stretches well beyond what the statute allows," warned health policy lawyer, Paul Kim, per the New York Post.&nbsp;
Investors in the healthcare sector may choose to mitigate risk and exposure to PBMs through a diversified healthcare ETF like the SPDR Select Health Care Sector Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) which holds shares of pharmaceuticals, health care equipment and supplies and health care providers.&nbsp;
An ETF like the iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITI#NYSE">ITI</a>) which tracks the Dow Jones U.S. Select Medical Equipment Index and invests in leading U.S. medical device companies also offers exposure to the healthcare industry while reducing exposure to pharmaceutical benefit managers.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45319531/cathie-wood?utm_source=articleShare">Cathie Wood Says AI Will &#8216;Disrupt The Traditional World Order&#8217; And Replace Search Engines Like Google</a>&nbsp;</li>
</ul>
Image: Shutterstock

Large Cap

Sector ETFs

Specialty ETFs

Movers

ETFs

Trump Again Promises Lower Drug Prices By 'Cutting Out Middlemen' Like UnitedHealth, CVS: Will It Work This Time?

CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) shares trading lower Tuesday. President Donald Trump on Monday signed an executive order aimed at reducing the cost <a href="https://www.benzinga.com/24/12/42517567/cvs-cigna-unitedhealth-shares-slide-as-trump-targets-drug-middleman">of prescription drugs.</a>
What To Know: According to the Wall Street Journal, the executive order directs Health Secretary Robert F. Kennedy to coordinate with pharmaceutical companies over the next month to lower drug prices. It also directs both the U.S. Trade Representative and the Commerce Department to take steps to combat unreasonable and discriminatory policies in foreign countries.
The order essentially aims to tie U.S. drug prices to those paid by other countries, many of which pay less due to government-negotiated rates. Trump said the order equalizes costs, arguing that Americans have been subsidizing cheaper prices abroad.
It also allows for Kennedy to impose rules and restrictions on drug companies and imports, if the companies don&#8217;t lower prices within 180 days.
The order doesn't clarify whether the pricing changes would affect Medicare or Medicaid.
CVS owns CVS Caremark and Cigna owns Express Scripts, both of which operate as pharmacy benefit managers (PBM). Investors may be reacting to the executive order's potential to undercut PBM revenues by tying U.S. drug prices to international rates rather than prices negotiated by PBMs.
CVS and Cigna may also be under pressure after UnitedHealth <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance">suspended its guidance</a>, as investors consider whether the same factors could impact the broader industry.
Related Link: <a href="https://www.benzinga.com/25/05/45376610/xrp-price-surges-amid-bullish-technical-indicators-sees-more-institutional-adoption">XRP Price Surges Amid Bullish Technical Indicators, Sees More Institutional Adoption</a>
Price Action: At the time of writing, CVS shares are trading 4.83% lower at $61.73 and Cigna shares are trading 2.68% lower at $307.29, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro.</a>
Image: via Shutterstock

CVS Health, Cigna Stocks Dip Tuesday: What's Going On?

WIIM

ALHC

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Shares of health insurance stocks are trading lower after UnitedHealth suspended its 2025 outlook as medical expenditures were expected to be larger than anticipated.

Truist Securities analyst David Macdonald maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and raises the price target from $385 to $405.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Cigna Group, Raises Price Target to $405

Shares of health insurance stocks and pharmacy benefit mangers are trading lower amid President Trump's executive order on drug pricing.

<a href="https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html">https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html</a>
&nbsp;
<ul>
<li>President Donald Trump will revive a controversial policy that aims to slash drug costs by tying the amount the government pays for some medicines to lower prices abroad, White House officials said.</li>
<li>The order is a blow to the pharmaceutical industry, which is already bracing for Trump&#39;s planned tariffs on prescription drugs.</li>
<li>It is Trump&#39;s latest effort to try to rein in U.S. prescription drug prices, which are two to three times higher on average than those in other developed nations.</li>
</ul>
&nbsp;

MRNA

'Trump To Sign Order To Cut Some U.S. Drug Prices To Match Those Abroad' - CNBC

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$76.00</td>
<td>$46.3K</td>
<td>2.0K</td>
<td>4.3K</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$105.00</td>
<td>$32.6K</td>
<td>275</td>
<td>1.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$75.00</td>
<td>$45.3K</td>
<td>334</td>
<td>1.1K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$80.00</td>
<td>$32.1K</td>
<td>27</td>
<td>908</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$192.50</td>
<td>$25.0K</td>
<td>618</td>
<td>726</td>
</tr>
<tr>
<td>GH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$22.50</td>
<td>$46.7K</td>
<td>219</td>
<td>73</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/17/27</td>
<td>$500.00</td>
<td>$43.1K</td>
<td>494</td>
<td>41</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$790.00</td>
<td>$45.0K</td>
<td>160</td>
<td>12</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$490.00</td>
<td>$32.8K</td>
<td>21</td>
<td>8</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$280.00</td>
<td>$35.8K</td>
<td>1.7K</td>
<td>4</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option sweep that happens to be bullish, expiring in 7 day(s) on May 16, 2025. This event was a transfer of 315 contract(s) at a $76.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $46.3K, with a price of $147.0 per contract. There were 2065 open contracts at this strike prior to today, and today 4318 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with neutral sentiment. It expires in 133 day(s) on September 19, 2025. Parties traded 152 contract(s) at a $105.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $215.0 per contract. There were 275 open contracts at this strike prior to today, and today 1355 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 616 day(s) on January 15, 2027. Parties traded 27 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $45.3K, with a price of $1680.0 per contract. There were 334 open contracts at this strike prior to today, and today 1104 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a put option trade with bullish sentiment. It expires in 616 day(s) on January 15, 2027. Parties traded 6 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $32.1K, with a price of $5351.0 per contract. There were 27 open contracts at this strike prior to today, and today 908 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 7 day(s) on May 16, 2025. Parties traded 137 contract(s) at a $192.50 strike. This particular call needed to be split into 40 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $183.0 per contract. There were 618 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• For GH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), we notice a call option sweep that happens to be bullish, expiring in 224 day(s) on December 19, 2025. This event was a transfer of 22 contract(s) at a $22.50 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $46.7K, with a price of $2123.0 per contract. There were 219 open contracts at this strike prior to today, and today 73 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with neutral sentiment. It expires in 769 day(s) on June 17, 2027. Parties traded 10 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $43.1K, with a price of $4315.0 per contract. There were 494 open contracts at this strike prior to today, and today 41 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bullish sentiment. It expires in 98 day(s) on August 15, 2025. Parties traded 10 contract(s) at a $790.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $4500.0 per contract. There were 160 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be bearish, expiring in 161 day(s) on October 17, 2025. This event was a transfer of 5 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $32.8K, with a price of $6569.0 per contract. There were 21 open contracts at this strike prior to today, and today 8 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bullish, expiring in 616 day(s) on January 15, 2027. This event was a transfer of 4 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $35.8K, with a price of $8950.0 per contract. There were 1706 open contracts at this strike prior to today, and today 4 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ILMN

VKTX

VRTX

10 Health Care Stocks With Whale Alerts In Today's Session

Guggenheim analyst Jason Cassorla maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and raises the price target from $384 to $388.

Guggenheim Maintains Buy on Cigna Group, Raises Price Target to $388

Piper Sandler analyst Jessica Tassan maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $348 to $374.

Piper Sandler Maintains Overweight on Cigna Group, Raises Price Target to $374

Shares of Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) rose in early Monday trading after the company announced <a href="https://www.benzinga.com/general/health-care/25/05/45165804/cigna-ceo-says-strong-q1-earnings-increased-outlook-reflect-strength-in-growth-platforms">upbeat first-quarter results on Friday</a>.
Here are some key analyst takeaways.
<ul>
<li>Guggenheim Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62289c8626d7930001219176/jason-cassorla">analyst Jason Cassorla</a> maintained a Buy rating on the stock.</li>
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/613f2550b4035700018da9d8/jessica-tassan">analyst Jessica Tassan</a> maintained an Overweight rating, while raising the price target from $348 to $374.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Guggenheim Securities: Cigna reported its first-quarter earnings at $6.74 per share, beating consensus of $6.35 per share. The company&#8217;s revenues were "well ahead of expectations, particularly within Evernorth," Cassorla said. Evernorth revenues grew by around 16% year-on-year to $53.68 billion, topping consensus of $50.3 billion, while Healthcare revenues rose 9% to $14.48 billion, surpassing consensus of $12.15 billion, he added.
Management raised the full-year earnings guidance by 10 cents per share. "Consensus comparisons are difficult due to timing related to the Medicare divestiture, but the lift in Healthcare pre-tax earnings guide against the delay in Medicare sale (runs at higher MLR) vs company expectations suggests favorable cost trend development for remaining businesses," he wrote.
Piper Sandler: Cigna's earnings beat was led by Cigna Healthcare, Tassan said. Cigna Healthcare's MLR (medical loss ratio) came in at 82.2%, better than expectations of around 83%, despite headwinds from the timing of the Medicare Advantage sale to HCSC, which suggests that "trends in the continuing businesses were considerably better than forecast," she added.
The analyst stated that the raised guidance for Cigna Healthcare looks conservative based on the trends in the first quarter and utilization so far this year. 
"Guidance called for 55.0% of Cigna Healthcare operating income in 1H25, with slightly more than half occurring in 1Q25," she added.
CI Price Action: Shares of Cigna had risen by 0.13% to $334.33 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45045012/sabre-divests-hospitality-arm-tpg-plans-debt-reductioncore-platform-focus">Healthcare Stocks Decline After Trump Signs Executive Order On Price Transparency</a></li>
</ul>

Analyst Color

Earnings Beats

Reiteration

Cigna Packs Healthy Punch As Q1 Beat Sends Shares Higher, Analysts Raise Targets

Guggenheim analyst Jason Cassorla reiterates Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) from Buy to Buy.

Guggenheim Reiterates Buy on Cigna Groupto Buy

Morgan Stanley analyst Erin Wright maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $379 to $390.

Comments

Cigna Group

Cigna Group (CI) オプション

Loading...

ニュース

パートナーシップ

ベンジンガ・グローバル